ORTIZ, MarÃa Clara; CARRILLO, Diana Cristina
 yÂ
CEPEDA, Magda Cristina. Uso "off label" de Stents Coronarios Medicados: Factores pronósticos en el Seguimiento. Rev Chil Cardiol [online].
2012,
vol.31, n.2, pp. 112-117.
ISSN 0718-8560.Â
doi: 10.4067/S0718-85602012000200005.
|
|
2. RABINOVITZ A, BIER DM, WAGMAN GM, CHARLAP E, NAZARI R, GHITELMAN J, et al. Association between off-label use of drug-eluting stents and subsequent stent thrombosis: a case-control analysis. J Invasive Cardiol. 2010;22:15-9. [ Links ] 3. FARB A, BOAM AB. Stent thrombosis redux--the FDA perspective. N. Engl. J. Med. 2007;356:984-7. [ Links ] 4. GUALANO SK, GURM HS, SHARE D, SMITH D, ARONOW HD, LALONDE T, et al. Temporal trends in the use of drug-eluting stents for approved and off-label indications: a longitudinal analysis of a large multicenter percutaneous coronary intervention registry. Clin Cardiol. 2010;33:111-6. [ Links ] 5. COOK S, WENAWESER P. Off-label use and the spectre of drug-eluting stent thrombosis. Circ Cardiovasc Interv. 2009;2:273-6. [ Links ] 6. BEOHAR N, MEYERS SN, ERDOGAN A, HARINSTEIN ME, PIEPER K, GAGNON S, et al. Off-label use of drug-elu-ting versus bare metal stents: a lesion-specific systematic review of long-term outcomes. J Interv Cardiol. 2010;23:528-45. [ Links ] 7. AUSTIN D, OLDROYD KG, MCCONNACHIE A, SLACK R ETEIBA H, FLAPAN AD, et al. Drug-eluting stents versus bare-metal stents for off-label indications: a propensity score-matched outcome study. Circ Cardiovasc Interv. 2008;1:45-52. [ Links ] |